The Epstein – Barr virus (EBV) monovaccine market consists of preventive vaccines aimed at reducing the risk of infectious mononucleosis caused due to primary EBV infection. EBV monovaccine provides immunity against EBV by inducing virus-specific T cells and antibody responses. It is an effective intervention to curb the rising burden of EBV-associated diseases.
The global EBV monovaccine market is estimated to be valued at US$ 12.01 Tn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the EBV monovaccine market are Kimberly-Clark, 3M Company, uvex group, The Gerson Company, Kowa Company Ltd., Moldex-Metric Inc., Bunzl PLC (SAS Safety Corp.), and Honeywell International Inc., among others. EBV monovaccine offers potential opportunities to target high-risk groups like military personnel and adolescents. Growing awareness about EBV pathogenesis and available intervention strategies are fueling the demand for EBV monovaccines globally. With rising EBV disease burden worldwide, leading players are exploring new markets for geographical expansion and product access in Asia Pacific and Middle Eastern countries.
Market drivers
The increasing epidemiology of infectious mononucleosis caused due to Monovaccine (Epstein – Barr virus) Market Size is a major market driver. As per recent studies, 90% of adults globally have been exposed to EBV by the age of 40. This translates to a huge pool of susceptible population for EBV infection and related diseases. EBV monovaccine, by providing protective immunity, can help control the spread of EBV and subsequent infections. This is expected to boost the monovaccine market during the forecast period.
PEST Analysis
Political: Regulations related to vaccine production standards and clinical trials. Government funding and initiatives for research and development of new vaccines.
Economic: Global and regional economic growth impacting healthcare spending. Cost of developing and manufacturing Monovaccine (Epstein – Barr virus) Market. Return on investment for pharmaceutical companies.
Social: Disease awareness and prevention. Healthcare access and affordability. Changes in lifestyle and risk of infection. Acceptance of new vaccines.
Technological: Advances in biotechnology and molecular biology. Development of new vaccine production methods and platforms. Digital health technologies for vaccine distribution and monitoring.
Geographical regions where market in terms of value is concentrated:
North America currently accounts for the largest share of the global monovaccine market for Epstein – Barr virus due to advanced healthcare infrastructure and high healthcare spending in countries like the United States. Countries in Europe such as Germany, France and United Kingdom are also major markets.
Fastest growing region for the market:
The Asia Pacific region is expected to experience the highest growth over the forecast period owing to improving economic conditions, rising medical tourism, increasing government funding for healthcare and growing focus on infectious disease prevention in populous countries such as China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author – Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile